Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Axilla; Breast Clear all
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
88
States / cities
Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial

NCT00001250
View directory record Official record
Conditions
Breast Neoplasm, Neoplasm Metastasis
Interventions
preoperative dose intense chemotherapy (FLAC/G-CSF)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 3 Interventional

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

NCT02780401
View directory record Official record
Conditions
HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Seattle, Washington • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 10, 2026, 6:15 PM EDT
Recruiting Not applicable Interventional

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma

NCT03941756
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Melanoma
Interventions
Indocyanine Green, Lymphangiography, Lymphovenous Bypass
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 1Phase 2 Interventional

3-Dimensional Conformal Radiation Therapy In Treating Women With Stage I or Stage II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection

NCT00068263
View directory record Official record
Conditions
Breast Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Jun 10, 2026, 6:15 PM EDT
Active, not recruiting Phase 2 Interventional

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

NCT03384914
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
Interventions
DC1 Vaccine, WOKVAC Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel in Node Positive Adjuvant Breast Cancer

NCT00688740
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, 5-fluorouracil, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 15, 2011 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation

NCT00575744
View directory record Official record
Conditions
Breast Cancer
Interventions
Sentinel Node Biopsy
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Early Phase 1 Interventional

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer

NCT03411070
View directory record Official record
Conditions
Positive Axillary Lymph Node, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Implanted Medical Device, Therapeutic Conventional Surgery
Device · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jun 10, 2026, 6:15 PM EDT
Recruiting Not applicable Interventional

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

NCT07140172
View directory record Official record
Conditions
Breast Cancer
Interventions
Axillary lymph node dissection (ALND), Axillary radiotherapy (ART)
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
4
States / cities
Bethesda, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional

Selective Image Guided Resection of Axillary Lymph Nodes

NCT01880645
View directory record Official record
Conditions
Breast Cancer
Interventions
Fine Needle Aspiration (FNA), Ultrasound, Breast Surgery + Lymph Node Removal
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 4 Interventional Results available

Pulsed Electromagnetic Fields (PEMF) and Post-Axillary Surgery Morbidity

NCT01255631
View directory record Official record
Conditions
Shoulder Symptoms After Lymph Node Dissection
Interventions
PEMF Device, Sham PEMF Device
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Jun 10, 2026, 6:15 PM EDT
Withdrawn Not applicable Interventional

Using Magnetic Resonance Spectroscopy With MRI to Non-invasively Determine Breast Cancer Extent of Disease

NCT00312637
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic Resonance Spectroscopy
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
25 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 3 Interventional

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

NCT00002772
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, carmustine, cisplatin, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jun 10, 2026, 6:15 PM EDT
Recruiting Not applicable Interventional

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

NCT05890677
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Surgical Intervention, Conservative Complex Physical Decongestion Therapy
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Recruiting Not applicable Interventional

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

NCT03796559
View directory record Official record
Conditions
Breast Cancer, Axillary Lymph Nodes
Interventions
Magseed Marker
Device
Lead sponsor
Endomagnetics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 3 Interventional

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

NCT00002646
View directory record Official record
Conditions
Breast Cancer
Interventions
fenretinide, tamoxifen citrate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional

Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer

NCT02046057
View directory record Official record
Conditions
Breast Cancer
Interventions
PNB of SLN
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer

NCT01771666
View directory record Official record
Conditions
Breast Cancer
Interventions
SPY Elite Imaging, Indocyanine Green, Isosulfan blue, 99technetium-sulfur colloid radiolabel
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional Results available

Upper Extremity Lymphatic Mapping for Breast Cancer Patients

NCT00717886
View directory record Official record
Conditions
Breast Cancer, Axillary Lymph Node Dissection
Interventions
isosulfan blue dye
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Jun 10, 2026, 6:15 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319
View directory record Official record
Conditions
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Interventions
DS-8201a, T-DM1
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
126
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Recruiting Phase 2 Interventional

A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer

NCT06327490
View directory record Official record
Conditions
Breast Cancer
Interventions
ICG-guided manual lymphatic drainage, Traditional manual lymphatic drainage, Indocyanine green
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional

Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients

NCT00507611
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Sentinel node mapping
Procedure
Lead sponsor
Stephen Povoski
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Jun 10, 2026, 6:15 PM EDT